Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Engimmune Therapeutics Logo
Engimmune Therapeutics Growth Score
22
CB Rank
53477
Heat Score
28
Engimmune Therapeutics is a platform and product development company engineering next-generation T cell receptor therapies.
Founded
obfuscation
PrivateSeed Basel, Basel-Stadt, Switzerland11-50 www.engimmune.com
Biotechnology
Therapeutics
Overview

Engimmune Therapeutics
Total Funding
obfuscation
Growth Score
22
Heat Score
28

Total Funding
obfuscation
obfuscation
Seed raised
obfuscation
Growth Score22
-1 pts
in past quarter
Heat Score 28
-7 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Engimmune Therapeutics

CB Rank
53477
Engimmune Therapeutics is a platform and product development company engineering next-generation T cell receptor therapies.
Founded
obfuscation
PrivateSeed Basel, Basel-Stadt, Switzerland11-50 www.engimmune.com
Biotechnology
Therapeutics

Funding Rounds

Seed
OBF
in
obfuscation
Pre-Seed
OBF
in
obfuscation

Key People

Details

Legal Name Engimmune Therapeutics AG
Operating Status Active
Company Type For Profit
Founders  Rodrigo Vazquez Lombardi
About the Company
Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences engineering highly potent and specific therapies based on T cell receptors (TCR) targeting solid tumors.
Predictions & Insights

Growth Prediction

See this Growth Prediction
Top Contributing Factors
Growth Insight

Products & Services

ENGI-003
A trispecific soluble T-cell receptor therapy targeting glypican-3 in hepatocellular carcinoma to enhance T cell function and combat tumor immune suppression.
ENGI-004
An inhibitory soluble T-cell receptor therapy targeting an MHC-related receptor to suppress immune responses in inflammatory diseases like atopic dermatitis and ulcerative colitis.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 2
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Seed Round - Engimmune Therapeutics Logo
Seed Round - Engimmune Therapeutics
3
obfuscation
Novo Holdings, Pureos BioventuresSeed
obfuscation
Seed Round - Engimmune Therapeutics Logo
Seed Round - Engimmune Therapeutics
3
obfuscation
Novo Holdings, Pureos BioventuresSeed
obfuscation
Seed Round - Engimmune Therapeutics Logo
Seed Round - Engimmune Therapeutics
3
obfuscation
Novo Holdings, Pureos BioventuresSeed
obfuscation
Seed Round - Engimmune Therapeutics Logo
Seed Round - Engimmune Therapeutics
3
obfuscation
Novo Holdings, Pureos BioventuresSeed
obfuscation
Seed Round - Engimmune Therapeutics Logo
Seed Round - Engimmune Therapeutics
3
obfuscation
Novo Holdings, Pureos BioventuresSeed

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 2
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Seed Round - Engimmune Therapeutics Logo
Seed Round - Engimmune Therapeutics
3
obfuscation
Novo Holdings, Pureos BioventuresSeed
obfuscation
Seed Round - Engimmune Therapeutics Logo
Seed Round - Engimmune Therapeutics
3
obfuscation
Novo Holdings, Pureos BioventuresSeed
obfuscation
Seed Round - Engimmune Therapeutics Logo
Seed Round - Engimmune Therapeutics
3
obfuscation
Novo Holdings, Pureos BioventuresSeed
obfuscation
Seed Round - Engimmune Therapeutics Logo
Seed Round - Engimmune Therapeutics
3
obfuscation
Novo Holdings, Pureos BioventuresSeed
obfuscation
Seed Round - Engimmune Therapeutics Logo
Seed Round - Engimmune Therapeutics
3
obfuscation
Novo Holdings, Pureos BioventuresSeed

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 3 Board Members and Advisors 3 Contacts 14

Employee Profiles

Board Members and Advisors

News

News and Press

News•May 10, 2024
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 17, 2024
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 17, 2024
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 17, 2024
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

128
-26.44%
 in past month

Active Website Tech Count

25Engimmune Therapeutics is actively using 25 technologies for its website, according to BuiltWith. These include U.S. Server Location, LetsEncrypt, and  HSTS.

Total IP

1Engimmune Therapeutics has 1 registered patent in the 'Organic Chemistry' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Engimmune Therapeutics's headquarters? Engimmune Therapeutics is located in Basel, Basel-Stadt, Switzerland.Who invested in Engimmune Therapeutics? Engimmune Therapeutics has 4 investors including Novo Holdings and  Pureos Bioventures.When was the last funding round for Engimmune Therapeutics? Engimmune Therapeutics closed its last funding round on
obfuscation
from a Seed round.Who are Engimmune Therapeutics's competitors? Alternatives and possible competitors to Engimmune Therapeutics may include TScan Therapeutics, Adaptive Biotechnologies, and  Repertoire Immune Medicines.How much funding has Engimmune Therapeutics raised to date? Engimmune Therapeutics has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(35d1611 1)
|